Bretisilocin Drug Asset Due Diligence Report 2026

This Bretisilocin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Bretisilocin can convert its Small molecule drug profile and 5-HT2A receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Bretisilocin (query alias: Bretisilocin)
Modality / target	Small molecule drug; 5-HT2A receptor; 5-HT2A receptor agonists
Highest global status	Phase 2
Originator	Gilgamesh Pharmaceuticals, Inc.
Active developers	AbbVie, Inc., Gilgamesh Pharmaceuticals, Inc.

The MCP disease footprint includes Depressive Disorder, Major. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06236880	Phase 2	Recruiting	124	Safety and Tolerability (Part A, B, and C)
NCT07604558	Phase 1	Recruiting	26	Number of Participants Experiencing Adverse Events
NL-OMON56273	Not Applicable	Recruiting	84	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)

Phase 2; n=40; evaluation: Positive. Reported fields: AE = GM-2505 was well tolerated with no serious adverse events. The majority of adverse events were mild and typically resolved within two hours following administration. ; AE = GM-2505 was well tolerated with no serious adverse events. The majority of adverse events were mild and typically resolved within two hours following administration.

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: DOMR(psychedelic effects) = 60 - 90 minute

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Bretisilocin addresses Depressive Disorder, Major. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-08-25	AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin	Phase 2	US$1,200.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combinations of peripheral 5-HT2a receptor antagonists and central 5-HT2a receptor agonists”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO